The Ca2+ Channel Blocker Verapamil Inhibits the In Vitro Activation and Function of T Lymphocytes: A 2022 Reappraisal
Open Access
- 15 July 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (7) , 1478
Abstract
Ca2+ channel blockers (CCBs) are commonly used to treat different cardiovascular conditions. These drugs disrupt the intracellular Ca2+ signaling network, inhibiting numerous cellular functions in different cells, including T lymphocytes. We explored the effect of the CCB verapamil on normal human peripheral blood T cell activation, proliferation, and cytokine production. Cells were activated by ligating CD3 or CD3/CD28 in the presence or absence of verapamil, and the expression of activation-induced cell surface molecules (CD25, CD40L, CD69, PD-1, and OX40), cell proliferation, and cytokine release were assessed by flow cytometry. Verapamil exerted a dose-dependent inhibitory effect on the expression of all the activation-induced cell surface molecules tested. In addition, verapamil diminished T cell proliferation induced in response to CD3/CD28 stimulation. Likewise, the production of Th1/Th17 and Th2 cytokines was also reduced by verapamil. Our data substantiate a potent in vitro suppressive effect of verapamil on T lymphocytes, a fact that might be relevant in patients receiving CCBs.Keywords
Funding Information
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (A1-S-15601, IN212519)
- Universidad Nacional Autónoma de México (A1-S-15601, IN212519)
This publication has 73 references indexed in Scilit:
- Nuclear Factor of Activated T Cells 1 (NFAT1)-induced Permissive Chromatin Modification Facilitates Nuclear Factor-κB (NF-κB)-mediated Interleukin-9 (IL-9) TransactivationJournal of Biological Chemistry, 2012
- Calcium Channel BlockersThe Journal of Clinical Hypertension, 2011
- Verapamil Block of T-Type Calcium ChannelsMolecular Pharmacology, 2011
- Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulationJournal of Translational Medicine, 2010
- CD28 co‐signaling in the adaptive immune responseSelf/Nonself, 2010
- Calcium-Antagonist DrugsNew England Journal of Medicine, 1999
- Lymphocyte calmodulin and its participation in the stimulation of T lymphocytes by mitogenic lectinsBiology of the Cell, 1992
- Potent and specific inhibition of IL-8-, IL-1α- and IL-1β-inducedin vitro human lymphocyte migration by calcium channel antagonistsBiochemical and Biophysical Research Communications, 1989
- Effect of cations and cation channel blockers on human natural killer cellsInternational Journal of Immunopharmacology, 1985
- Clinical Pharmacokinetics of VerapamilClinical Pharmacokinetics, 1984